Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase II Study of Dornase Alfa and Cisplatin in Refractory Germ Cell Cancer.

NCT07121322 is registered in ClinicalTrials.gov with National Cancer Institute, Slovakia as lead sponsor.

NCT NCT07121322
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07121322 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase II Study of Dornase Alfa and Cisplatin in Refractory Germ Cell Cancer.
Lead sponsor
National Cancer Institute, Slovakia
Phase
Phase 2
Overall status
Recruiting
Start date
July 30, 2025
Completion date
July 30, 2028
Enrollment
33 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

dornase alfa, refractory germ cell tumors